UCB announced that it Neupro patch is now back available in US retail pharmacies for the treatment of Parkinson’s disease (PD) andrestless legs syndrome (RLS). We remind that the FDA gave green light already for a re-introduction in April 2012.
Neupro was previously approved by the FDA for the treatment of early stage PD, but was withdrawn in 2009 from the US market following crystallization issues in the patch. Similar issues in Europe were resolved via a cold-chain distribution system, but the US required a new formulation of the patch, which is now approved.
The US is the biggest market for this product, especially for the RLS indication. An estimated 3-10% of US population is thought to have some form of RLS. We remind that last year, Neupro achieved ex-US sales of € 95m.
Today’s news is no surprise given the earlier green light from the FDA. Accumulate maintained.
CURRENT PRICE € 40.24
TARGET PRICE € 40.00